nach oben

Erschienen in:

11.11.2023 | Original Article

Fat-free mass index is a feasible predictor of insulin resistance in women with polycystic ovary syndrome: Evidence from a cross-sectional study

verfasst von: Jinru Guo, Baiwei Lin, Rui Niu, Wenjing Lu, Chunmei He, Mulin Zhang, Yinxiang Huang, Xueqin Chen, Changqin Liu

Erschienen in: Endocrine | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Insulin resistance (IR) and adipose tissue amplify the metabolic and reproductive outcomes in women with polycystic ovary syndrome (PCOS). It has been widely discussed that body composition influences metabolic health. Still, limited studies were focused on the role of the fat-free mass index (FFMI) in assessing IR in PCOS women.

Aims

We aimed to explore the associations between FFMI/fat mass index (FMI) and IR in women with PCOS and assess the role of FFMI in predicting IR in women with PCOS.

Methods

In the current cross-sectional study, women with PCOS aged between 18 and 40 years were enrolled from October 2018 to July 2022. Baseline demographic information was obtained using standardized self-administered questionnaires. Anthropometric, biochemical, and hormonal information was measured and recorded by investigators. Pearson’s correlation and multivariable logistical regression were used to analyze the associations of FFMI/FMI and IR. In addition, receiver operating characteristic (ROC) curves were implied to measure the predictive role of FFMI/FMI for IR in women with PCOS.

Results

A total of 371 women with PCOS, reproductive age (27.58 ± 4.89) were enrolled. PCOS women with IR have higher levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), homeostatic model assessment of insulin resistance (HOMA-IR), FMI, and FFMI than that without IR. FMI (r = 0.492, p < 0.001) and FFMI (r = 0.527, p < 0.001) were positively associated with IR. After adjusting for potential confounders, FMI and FFMI were significantly associated with IR in PCOS women, and the OR was 1.385 (95%CI: 1.212–1.583) and 2.306 (95%CI: 1.675–3.174), respectively. Additionally, the FFMI (0.847, 95%CI: 0.784–0.888) has a larger area of ROC (AUC) than the FMI (0.836, 95%CI: 0.799–0.896), while there is no difference in predicting IR (95%CI: −0.18–0.41, p = 0.456).

Conclusion

These results indicated that FFMI and FMI could significantly increase the risk of IR, both of which could be feasible predictors of IR in PCOS women.

A.E. Joham et al. “Polycystic ovary syndrome”. Lancet Diabetes Endocrinol 10(9), 668–680 (2022)CrossRefPubMed

E. Stener-Victorin et al. “Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome?”. J Clin Endocrinol Metab 95(2), 810–819 (2010)CrossRefPubMed

D. Jena et al. “Study of visceral and subcutaneous abdominal fat thickness and its correlation with cardiometabolic risk factors and hormonal parameters in polycystic ovary syndrome.”. Indian J Endocrinol Metab 22(3), 321–327 (2018)CrossRefPubMedPubMedCentral

C.J. Glueck, N. Goldenberg, “Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics”. Metabolism 92, 108–120 (2019)CrossRefPubMed

HOMA-IR: A Test of Insulin Resistance + Ways to Decrease It (Last updated: January 15, 2021 at https://labs.selfdecode.com/blog/homa-ir/)

D.L. Tahapary et al. “Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride/glucose index”. Diabetes Metab Syndrom 16(8), 102581 (2022)CrossRef

T.B. VanItallie et al. “Height-normalized indices of the body’s fat-free mass and fat mass: potentially useful indicators of nutritional status”. Am J Clin Nut 52(6), 953–959 (1990)CrossRef

P. Patel, N. Abate, “Body fat distribution and insulin resistance”. Nutrients 5(6), 2019–2027 (2013)CrossRefPubMedPubMedCentral

S.C. Larsson et al. “Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study”. Eur Heart J 41(2), 221–226 (2020)CrossRefPubMed

10.

J.C. Lagacé et al. “A counterintuitive perspective for the role of fat-free mass in metabolic health”. J Cachexia Sarcopenia Muscle 11(2), 343–347 (2020)CrossRefPubMedPubMedCentral

11.

F. Tosi et al. “Total body fat and central fat mass independently predict insulin resistance but not hyperandrogenemia in women with polycystic ovary syndrome”. J Clin Endocrinol Metab 100(2), 661–669 (2015)CrossRefPubMed

12.

A. Aydogdu et al. “Increase in subcutaneous adipose tissue and fat free mass in women with polycystic ovary syndrome is related to impaired insulin sensitivity”. Gynecol Endocrinol 29(2), 152–155 (2013)CrossRefPubMed

13.

C.T. Tay et al. “Updated adolescent diagnostic criteria for polycystic ovary syndrome: impact on prevalence and longitudinal body mass index trajectories from birth to adulthood”. BMC Med 18(1), 389 (2020)CrossRefPubMedPubMedCentral

14.

X. Zeng et al. “Staying up late increases cardiovascular disease risk in women with polycystic ovary syndrome”. Hum Reprod 38(7), 1359–1367 (2023)CrossRefPubMed

15.

W.A. Salameh et al. “Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria”. Fertil Steril 101(4), 1135–1141.e1132 (2014)CrossRefPubMedPubMedCentral

16.

R. Ross et al. “Waist circumference as a vital sign in clinical practice: A Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity”. Nat Rev Endocrinol 16(3), 177–189 (2020)CrossRefPubMedPubMedCentral

17.

M. Saghafi-Asl et al. “Lipid profile in relation to anthropometric indices and insulin resistance in overweight women with polycystic ovary syndrome”. Health Promot Perspect 3(2), 206–216 (2013)PubMedPubMedCentral

18.

B. Tang et al. “Waist-hip Ratio (WHR), a better predictor for prostate cancer than Body Mass Index (BMI): Results from a Chinese hospital-based biopsy cohort”. Sci Rep 7, 43551 (2017)CrossRefPubMedPubMedCentral

19.

C.T. Bramante et al. “BMI metrics and their association with adiposity, cardiometabolic risk factors, and biomarkers in children and adolescents”. Int J Obes (Lond) 46(2), 359–365 (2022)CrossRefPubMed

20.

M.G. Nikolova et al. “Correlations of serum vitamin D with metabolic parameters in adult outpatients with different degrees of overweight/obesity coming from an urban community”. Acta Endocrinol 14(3), 375–383 (2018)

21.

A. Ghachem et al. “Fat-free mass and glucose homeostasis: is greater fat-free mass an independent predictor of insulin resistance?”. Aging Clin Exp Res 31(4), 447–454 (2019)CrossRefPubMed

22.

J.F. Ascaso et al. “Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism”. Diabetes Care 26(12), 3320–3325 (2003)CrossRefPubMed

23.

E.R. DeLong et al. “Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach”. Biometrics 44(3), 837–845 (1988)CrossRefPubMed

24.

Y. Chen et al. “Neck circumference is a good predictor for insulin resistance in women with polycystic ovary syndrome”. Fertil Steril 115(3), 753–760 (2021)CrossRefPubMed

25.

T. Abe et al. “Influence of adipose tissue mass on DXA-derived lean soft tissue mass in middle-aged and older women”. Age 37(1), 9741 (2015)CrossRefPubMed

26.

B. Ahmed et al. “Adipose tissue and insulin resistance in obese”. Biomed Pharmacother 137, 111315 (2021)CrossRefPubMed

27.

S.E. Kahn et al. “Mechanisms linking obesity to insulin resistance and type 2 diabetes”. Nature 444(7121), 840–846 (2006)CrossRefPubMed

28.

W.J. Miller et al. “Effect of strength training on glucose tolerance and post-glucose insulin response”. Med Sci Sports Exerc 16(6), 539–543 (1984)CrossRefPubMed

29.

M. Szczypaczewska et al. “Glucose tolerance and insulin response to glucose load in body builders”. Int J Sports Med 10(1), 34–37 (1989)CrossRefPubMed

30.

J.C. Lagacé et al. “Increased odds of having the metabolic syndrome with greater fat-free mass: counterintuitive results from the National Health and Nutrition Examination Survey database”. J Cachexia Sarcopenia Muscle 13(1), 377–385 (2022)CrossRefPubMed

31.

R.A. Merchant et al. “Relationship of Fat Mass Index and Fat Free Mass Index with Body Mass Index and Association with Function, Cognition and Sarcopenia in Pre-Frail Older Adults”. Front Endocrinol 12, 765415 (2021)CrossRef

32.

P. Anagnostis et al. “Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences”. Metabolism 86, 33–43 (2018)CrossRefPubMed

33.

C. Tong et al. “Insulin resistance, autophagy and apoptosis in patients with polycystic ovary syndrome: Association with PI3K signaling pathway”. Front Endocrinol 13, 1091147 (2022)CrossRef

34.

K. Perreault et al. “Association between fat free mass and glucose homeostasis: Common knowledge revisited”. Ageing Res Rev 28, 46–61 (2016)CrossRefPubMed

35.

B.B. Groen et al. “Skeletal muscle capillary density and microvascular function are compromised with aging and type 2 diabetes”. J Appl Physiol 116(8), 998–1005 (2014)CrossRefPubMed

Titel: Fat-free mass index is a feasible predictor of insulin resistance in women with polycystic ovary syndrome: Evidence from a cross-sectional study
verfasst von: Jinru Guo
Baiwei Lin
Rui Niu
Wenjing Lu
Chunmei He
Mulin Zhang
Yinxiang Huang
Xueqin Chen
Changqin Liu
Publikationsdatum: 11.11.2023
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-023-03591-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Fat-free mass index is a feasible predictor of insulin resistance in women with polycystic ovary syndrome: Evidence from a cross-sectional study